Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles

Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles Substantial strides have been made in the field of biomarker research for mental illnesses over the past few decades. However, no US FDA-cleared blood-based biomarker tests have been translated into routine clinical practice. Here, we review the challenges associated with commercialisation of research findings and discuss how these challenges can impede scientific impact and progress. Overall evidence indicates that a lack of research funding and poor reproducibility of findings were the most important obstacles to commercialization of biomarker tests. Fraud, pre-analytical and analytical limitations, and inappropriate statistical analysis are major contributors to poor reproducibility. Increasingly, these issues are acknowledged and actions are being taken to improve data validity, raising the hope that robust biomarker tests will become available in the foreseeable future. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Trends in Biotechnology Elsevier

Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles

Loading next page...
 
/lp/elsevier/commercialisation-of-biomarker-tests-for-mental-illnesses-advances-and-RFiDY4CeeJ
Publisher
Elsevier
Copyright
Copyright © 2015 Elsevier Ltd
ISSN
0167-7799
D.O.I.
10.1016/j.tibtech.2015.09.010
Publisher site
See Article on Publisher Site

Abstract

Substantial strides have been made in the field of biomarker research for mental illnesses over the past few decades. However, no US FDA-cleared blood-based biomarker tests have been translated into routine clinical practice. Here, we review the challenges associated with commercialisation of research findings and discuss how these challenges can impede scientific impact and progress. Overall evidence indicates that a lack of research funding and poor reproducibility of findings were the most important obstacles to commercialization of biomarker tests. Fraud, pre-analytical and analytical limitations, and inappropriate statistical analysis are major contributors to poor reproducibility. Increasingly, these issues are acknowledged and actions are being taken to improve data validity, raising the hope that robust biomarker tests will become available in the foreseeable future.

Journal

Trends in BiotechnologyElsevier

Published: Dec 1, 2015

References

  • The economic cost of brain disorders in Europe
    Olesen, J.
  • Applications of blood-based protein biomarker strategies in the study of psychiatric disorders
    Chan, M.K.
  • Biomarkers of psychiatric diseases: current status and future prospects
    Kalia, M.; Costa, E.S.J.
  • A review on the acute phase response in major depression
    Maes, M.
  • Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways
    Schwarz, E.
  • The promise of biomarkers in diagnosing major depression in primary care: the present and future
    Redei, E.E.; Mehta, N.S.
  • The long journey of cancer biomarkers from the bench to the clinic
    Pavlou, M.P.
  • ELISA and multiplex technologies for cytokine measurement in inflammation and aging research
    Leng, S.X.
  • Antibody-based protein multiplex platforms: technical and operational challenges
    Ellington, A.A.
  • A simulation study of the number of events per variable in logistic regression analysis
    Peduzzi, P.
  • Diagnostic proteomics: will this impact the clinic?
    Sauer, S.
  • Implementation of proteomic biomarkers: making it work
    Mischak, H.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off